- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NYU Langone Creates Charity Fund for Complex Reconstructive Plastic Surgery for Patients in Need
NYU Langone has created a charity care fund for patients in need of complex reconstructive plastic surgery through a $15.1 million donated from international businessman and philanthropist Hansjörg Wyss.
NYU Langone has created a charity care fund for patients in need of complex reconstructive plastic surgery through a $15.1 million donated from international businessman and philanthropist Hansjörg Wyss. The charity fund, within the Hansjörg Wyss Department of Plastic Surgery, will provide high-quality reconstructive surgery care those underserved, underinsured, and uninsured.
The program, one of the only ones of its kind, will help eliminate disparities and barriers to care, regardless of a patient’s age, geographic location, or socioeconomic status. Conditions to be treated include deformities caused by trauma, cancer, illness, or birth.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
What We’re Reading: New HPV Screenings; Lung Cancer Pills; Migraine Relief Device
November 9th 2023A study suggests that human papillomavirus (HPV) screenings should be updated due to effective HPV vaccines; a new study shows that osimertinib (Tagrisso, AstraZeneca) reduced both the 5-year risk of recurrent cancer and the risk of death in patients with stage 1B to 3A lung cancer; a new smartphone-controlled technology could help those who suffer from migraines.
Read More
